LASA SUPERGENERICS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.2 INR | -4.07% |
|
-7.63% | -29.10% |
| Apr. 26 | Lasa Supergenerics CFO Steps Down | MT |
| Apr. 26 | Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs, and others. It is specialized in catalyst chemistry and manufactures anthelmintic/ veterinary API products with the production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located at Chiplun, Maharashtra.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -29.10% | 12.73M | |
| +18.66% | 8.74B | |
| +23.75% | 3.67B | |
| -0.42% | 3.25B | |
| +18.07% | 1.73B | |
| -16.99% | 1.38B | |
| -0.39% | 1.31B | |
| -26.05% | 1.24B | |
| -17.86% | 1.07B | |
| -6.77% | 976M |
- Stock Market
- Equities
- LASA Stock
- News Lasa Supergenerics Limited
- Lasa Supergenerics CFO Steps Down
